High cost of GLP-1s drives some to seek cheaper, unregulated versions
Despite some recent improvements, millions of Americans still face significant barriers in affording GLP-1s. At the same time, many patients have found alternative, cheaper paths to get their hands on unregulated versions. Stephanie Sy reports for our series, GLP-1s: Reshaping America.
2 across the spectrum. Choose a side on the bar to jump to it.
2 articles from 2 sources. Updated 7d ago.
Left
2 viewpointsCenter
0 viewpointsNo Center coverage yet.
A blind spot on this side of the story.
Right
0 viewpointsNo Right coverage yet.
A blind spot on this side of the story.